Skip to main
HELP

Cybin Inc (HELP) Stock Forecast & Price Target

Cybin Inc (HELP) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Helus Pharma is a clinical-stage biotechnology company with a promising pipeline of innovative serotonin-targeting compounds for treating mental health disorders such as depression and anxiety. The company's ongoing Phase 3 trials and their recent positive results from their Phase 2 trial demonstrate their potential to address the limitations of current treatments and make a significant impact in the neuropsychiatry sector. With a recently strengthened executive team and clear regulatory guidance for psychedelic therapies, the company is well-positioned for success.

Bears say

Helus Pharma is a clinical-stage pharmaceutical company focused on developing neuroactive compounds targeting serotonin pathways to treat mental health conditions. Despite ongoing enrollment in the pivotal Phase 3 EMBRACE study for their lead compound HLP003 and positive Phase 2 data for HLP004 in generalized anxiety disorder, there are inherent risks in the biotechnology sector, and Helus may face challenges in accessing the necessary capital to complete development. Additionally, a recent underwritten offering and potential delays in launch timelines lead to a lowered price target of $70 per share, though the company's upcoming Phase 3 APPROACH top-line readout remains on track and has potential to validate their novel therapeutic approach.

Cybin Inc (HELP) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cybin Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cybin Inc (HELP) Forecast

Analysts have given Cybin Inc (HELP) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Cybin Inc (HELP) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cybin Inc (HELP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.